Beijing Yiling Pharmaceutical

Yiling Pharmaceutical is a leading Chinese pharmaceutical company that specializes in the integration of Traditional Chinese Medicine (TCM) with modern medical technology. Founded by Academician Wu Yiling, the company is built upon the proprietary "Collateral Disease Theory," which serves as the foundation for its extensive R&D in cardiovascular, respiratory, and metabolic diseases. Its flagship product, Lianhua Qingwen, is a globally recognized treatment for influenza and played a significant role in the management of COVID-19. Beyond its dominant position in TCM, Yiling is aggressively expanding its pipeline into innovative small molecules and biologics, targeting high-need areas such as oncology and clinical nutrition. The company operates a complete industrial chain, including herbal cultivation, advanced manufacturing, and a robust academic marketing network.